Glenview Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Glenview Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-33,491	Closed	-$1.11M	–	320
2017 Q2	$1.11M	Sell	33,491 -17,143	-34%	-$531K	0.09%	157
2017 Q1	$1.63M	Sell	50,634 -44,557	-47%	-$1.52M	0.13%	126
2016 Q4	$3.45M	Buy	+95,191	New	+$3.8M	0.29%	92
2015 Q4	$13.3M	Buy	+202,299	New	+$12.5M	1.38%	22
2014 Q4	$13.2M	Buy	+230,183	New	+$12.8M	1.41%	23
2013 Q4	$9.57M	Buy	+238,700	New	+$9.4M	1.1%	35

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glenview Trust's TEVA Position: Q3 2017 in Review

Glenview Trust sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 33,491 shares — an estimated $1.11M sold.

Glenview Trust first reported a position in TEVA in Q4 2013 and held it in 6 quarters. The position peaked at $13.3M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Glenview Trust reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Glenview Trust sold 33,491 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.11M.
Glenview Trust first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Glenview Trust's Teva Pharmaceuticals position peaked at $13.3M in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Glenview Trust's 13F filing for Q3 2017, filed 7 Nov 2017.